Genomma Lab Internacional. de Dividends and Buybacks
Dividend criteria checks 3/6
Genomma Lab Internacional. de is a dividend paying company with a current yield of 2.99% that is well covered by earnings.
Key information
3.0%
Dividend yield
0.3%
Buyback Yield
Total Shareholder Yield | 3.3% |
Future Dividend Yield | 9.2% |
Dividend Growth | 7.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | Mex$0.800 |
Payout ratio | 23% |
Recent dividend and buyback updates
Recent updates
Investors Appear Satisfied With Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Prospects
Dec 02Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Sep 11With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For
Jul 12These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?
Nov 07Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?
Feb 24Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic
Sep 24Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts
Aug 01Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Mar 22Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?
Feb 15Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly
Nov 24Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock
Sep 08Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price
Jun 10Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?
May 24Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?
May 06Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%
Mar 13Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Feb 19Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?
Feb 02Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?
Jan 15What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?
Dec 28Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain
Dec 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, LAB B has been paying a dividend for less than 10 years.
Growing Dividend: LAB B's dividend payments have increased, but the company has only paid a dividend for 3 years.
Dividend Yield vs Market
Genomma Lab Internacional. de Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (LAB B) | 3.0% |
Market Bottom 25% (MX) | 2.5% |
Market Top 25% (MX) | 6.6% |
Industry Average (Pharmaceuticals) | 2.5% |
Analyst forecast (LAB B) (up to 3 years) | 9.2% |
Notable Dividend: LAB B's dividend (2.99%) is higher than the bottom 25% of dividend payers in the MX market (2.54%).
High Dividend: LAB B's dividend (2.99%) is low compared to the top 25% of dividend payers in the MX market (6.67%).
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (23.4%), LAB B's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (32.8%), LAB B's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/17 00:23 |
End of Day Share Price | 2025/01/17 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genomma Lab Internacional, S.A.B. de C.V. is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Antonio Hernandez Velez Leija | Actinver Case de Bolsa, S.A. de C.V. |
Benjamin Theurer | Barclays |
Miguel Ulloa Suárez | BBVA Corporate and Investment Bank |